2nd Tumour Models Summit Malmo Clarion Hotel Malmo Live, Malmo

Selecting and Optimising Predictive and Cost-Effective Models to Enhance Target Selection, Facilitate Biomarker Discovery and Achieve Clinical Translatability
2026 is set to reshape the future of preclinical oncology.

As we close out 2025 with the UK accelerating its roadmap to phase out animal testing and SillaJen securing a landmark FDA approval using only organoid efficacy data, the momentum has never been stronger. With immunomodulating therapies surging and preclinical development costs continuing to climb, the pressure is on for biopharma to cut attrition and de-risk every preclinical decision.

The message is clear: investing in more trustworthy, physiologically relevant, and cost-effective models is now mission-critical for successfully advancing assets worldwide.

Join your peers at the Tumour Models Summit Malmo as the industry’s leading minds unite to navigate this paradigm shift and define the future of preclinical oncology.